Key result
All measured serum concentrations were above the individually calculated lower dose-related concentration, whereas 24% of samples fell below published therapeutic reference ranges, indicating the DRC approach is superior for evaluating adherence.
Why the study?
Qualitative urine and serum or plasma screenings may lead to misinterpretations regarding antihypertensive drugs with prolonged detectability, prompting the need for a therapeutic drug monitoring method to assess adherence.
Does evaluation of serum drug concentrations using individually calculated lower dose-related concentrations improve adherence assessment compared to standard therapeutic reference ranges in hypertensive patients?
Observational (n=20)
No
Does evaluation of serum drug concentrations using individually calculated lower dose-related concentrations improve adherence assessment compared to standard therapeutic reference ranges in hypertensive patients?
Evaluating quantitative serum concentrations of antihypertensive drugs against individually calculated lower dose-related concentrations is superior to using standard therapeutic reference ranges for assessing medication adherence.
Answers are grounded in this paper and cite their sources.
May support DRC for adherence checks in practice; leaves open prospective outcome validation.
Detection of antihypertensive drugs in biological samples is an important tool to assess the adherence of hypertensive patients. Urine and serum/plasma screenings based on qualitative results may lead to misinterpretations regarding drugs with a prolonged detectability. The aim of the present study was to develop a method that can be used for therapeutic drug monitoring (TDM) of antihypertensive drugs with focus on adherence assessment. Therefore, a method for quantification of four diuretics and four β-blockers using high-performance liquid chromatography-mass spectrometric analysis (LC-MS/MS) of combined acidic and basic serum extracts was developed and validated. The method was applied to 40 serum samples from 20 patients in a supervised medication setting (trough and peak serum samples). Literature data on therapeutic concentration ranges, as well as dose-related drug concentrations (calculated from data of pharmacokinetic studies) were used to evaluate adherence assessment criteria. Concentrations were measured for bisoprolol (n = 9 patients), metoprolol (n = 7), nebivolol (n = 1), canrenone (n = 2, metabolite of spironolactone), hydrochlorothiazide (n = 10) and torasemide (n = 8). The measured concentrations were within the therapeutic reference ranges, except for 24% of the samples (mainly β-blockers). In contrast, all measured concentrations were above the lower dose-related concentration (DRC), which appears superior in evaluating adherence. In conclusion, the quantitative analysis of antihypertensive drugs in serum samples and its evaluation on the basis of the individually calculated lower DRC is a promising tool to differentially assess adherence. This method could possibly detect a lack of adherence or other causes of insufficient therapy more reliably than qualitative methods.
No takes yet. Share an insight, caveat, or question.
Ritscher et al. (2019) conducted an observational in Arterial hypertension (n=20). Dose-related concentration (DRC) approach vs. Therapeutic reference ranges was evaluated on Proportion of measured serum concentrations meeting adherence criteria. All measured serum concentrations were above the individually calculated lower dose-related concentration, whereas 24% of samples fell below published therapeutic reference ranges, indicating the DRC approach is superior for evaluating adherence.
Synapse has enriched 10 related papers. Consider them for comparative context: